Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hypertension

Economic burden and healthcare resource utilization

12 evidence topics · 12 sources

US spending on treatment of hypertension by type of care and payer, 2019
Resource use and costs with uncontrolled compared with controlled blood pressure in apparent treatment-resistant hypertension and stage 3 or 4 CKD: US claims, 3966 patients
Annual costs of cardiovascular health states used in the ICER model, 2025 US dollars
Health stateDirect medical costProductivity cost (modified societal perspective)
Hypertension (annual)“$3,211”Not reported
Stroke (acute and annual; annual for productivity)“$20,442 / $20,697”“$16,781”
Myocardial infarction (acute and annual; annual for productivity)“$25,832 / $17,106”“$19,028”
Coronary heart disease (annual)“$13,798”“$7,092”
Heart failure (index hospitalization and annual; annual for productivity)“$16,671 / $33,890”“$16,004”
End-stage kidney disease (annual)“$108,953”“$17,650”